These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18948412)

  • 41. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist.
    Murakami A; Takasugi H; Ohnuma S; Koide Y; Sakurai A; Takeda S; Hasegawa T; Sasamori J; Konno T; Hayashi K; Watanabe Y; Mori K; Sato Y; Takahashi A; Mochizuki N; Takakura N
    Mol Pharmacol; 2010 Apr; 77(4):704-13. PubMed ID: 20097776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and evaluation of arylalkoxy- and biarylalkoxy-phenylamide and phenylimidazoles as potent and selective sphingosine-1-phosphate receptor subtype-1 agonists.
    Evindar G; Satz AL; Bernier SG; Kavarana MJ; Doyle E; Lorusso J; Taghizadeh N; Halley K; Hutchings A; Kelley MS; Wright AD; Saha AK; Hannig G; Morgan BA; Westlin WF
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2315-9. PubMed ID: 19282175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.
    Kovarik JM; Riviere GJ; Neddermann D; Maton S; Hunt TL; Schmouder RL
    J Clin Pharmacol; 2008 Mar; 48(3):303-10. PubMed ID: 18218783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
    Gergely P; Nuesslein-Hildesheim B; Guerini D; Brinkmann V; Traebert M; Bruns C; Pan S; Gray NS; Hinterding K; Cooke NG; Groenewegen A; Vitaliti A; Sing T; Luttringer O; Yang J; Gardin A; Wang N; Crumb WJ; Saltzman M; Rosenberg M; Wallström E
    Br J Pharmacol; 2012 Nov; 167(5):1035-47. PubMed ID: 22646698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure.
    Tornatore KM; Venuto RC; Logue G; Davis PJ
    J Med; 1998; 29(3-4):159-83. PubMed ID: 9865456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
    Foster CA; Howard LM; Schweitzer A; Persohn E; Hiestand PC; Balatoni B; Reuschel R; Beerli C; Schwartz M; Billich A
    J Pharmacol Exp Ther; 2007 Nov; 323(2):469-75. PubMed ID: 17682127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Involvement of sphingosine 1-phosphate (S1P) receptor type 1 and type 4 in migratory response of mouse T cells toward S1P.
    Matsuyuki H; Maeda Y; Yano K; Sugahara K; Chiba K; Kohno T; Igarashi Y
    Cell Mol Immunol; 2006 Dec; 3(6):429-37. PubMed ID: 17257496
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.
    Kataoka H; Sugahara K; Shimano K; Teshima K; Koyama M; Fukunari A; Chiba K
    Cell Mol Immunol; 2005 Dec; 2(6):439-48. PubMed ID: 16426494
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of sphingosine 1-phosphate on morphological and functional responses in endothelia and venules after scalding injury.
    Liu X; Wu W; Li Q; Huang X; Chen B; Du J; Zhao K; Huang Q
    Burns; 2009 Dec; 35(8):1171-9. PubMed ID: 19520517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function.
    Idzko M; Hammad H; van Nimwegen M; Kool M; Müller T; Soullié T; Willart MA; Hijdra D; Hoogsteden HC; Lambrecht BN
    J Clin Invest; 2006 Nov; 116(11):2935-44. PubMed ID: 17080194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA
    Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice.
    Klingenberg R; Nofer JR; Rudling M; Bea F; Blessing E; Preusch M; Grone HJ; Katus HA; Hansson GK; Dengler TJ
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2392-9. PubMed ID: 17761943
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Attenuation of cell motility observed with high doses of sphingosine 1-phosphate or phosphorylated FTY720 involves RGS2 through its interactions with the receptor S1P.
    Kohno T; Igarashi Y
    Genes Cells; 2008 Jul; 13(7):747-57. PubMed ID: 18513330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Involvement of sphingosine-1-phosphate and S1P1 in angiogenesis: analyses using a new S1P1 antagonist of non-sphingosine-1-phosphate analog.
    Yonesu K; Kawase Y; Inoue T; Takagi N; Tsuchida J; Takuwa Y; Kumakura S; Nara F
    Biochem Pharmacol; 2009 Mar; 77(6):1011-20. PubMed ID: 19150609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations.
    D'Ambrosio D; Steinmann J; Brossard P; Dingemanse J
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):103-9. PubMed ID: 25519470
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population Pharmacokinetic Analysis of BMS-986166, a Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator, and Exposure-Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants.
    Bihorel S; Singhal S; Shevell D; Sun H; Xie J; Basdeo S; Liu A; Dutta S; Ludwig E; Huang H; Lin KJ; Fura A; Throup J; Girgis IG
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):8-21. PubMed ID: 33090733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enzymatic kinetics regarding reversible metabolism of CS-0777, a sphingosine 1-phosphate receptor modulator, via phosphorylation and dephosphorylation in humans.
    Inaba SI; Yamaguchi-Goto M; Tanaka-Takanaka K; Yonesu K; Sakurai H; Kubota K; Izumi T
    Xenobiotica; 2018 Mar; 48(3):258-268. PubMed ID: 28287856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P
    Lott D; Lehr T; Dingemanse J; Krause A
    Clin Pharmacokinet; 2017 Apr; 56(4):395-408. PubMed ID: 27638335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reining in FoxP3(+) regulatory T cells by the sphingosine 1-phosphate-S1P1 axis.
    Kim CH
    Immunol Cell Biol; 2009 Oct; 87(7):502-4. PubMed ID: 19652661
    [No Abstract]   [Full Text] [Related]  

  • 60. Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator.
    Krause A; Brossard P; D'Ambrosio D; Dingemanse J
    J Pharmacokinet Pharmacodyn; 2014 Jun; 41(3):261-78. PubMed ID: 24930034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.